November 15th 2023
Use of the surgical Epione robot will save a significant amount of time when performing surgery for patients with liver tumors and potentially other cancers, says Govindarajan Narayanan, MD.
November 14th 2023
October 13th 2023
Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
View More
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
View More
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass
Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Sorafenib/SBRT Yields OS Benefit in Locally Advanced Hepatocellular Carcinoma
January 21st 2023Patients diagnosed with locally advanced, hepatocellular carcinoma experience benefit in overall survival, progression-free survival, and time to disease progression following treatment with sorafenib and stereotactic body radiation therapy.
Tislelizumab Yields QOL Benefit Over Sorafenib in First-Line Hepatocellular Carcinoma
January 21st 2023Patients with unresectable hepatocellular carcinoma experienced an improvement in several health-related quality of life measures following treatment with first-line tislelizumab compared with sorafenib.
Durvalumab±Tremelimumab Efficacy Does Not Seem Affected by ADAs in Hepatocellular Carcinoma
January 20th 2023Findings from the phase 3 HIMALAYA trial indicate that durvalumab with or without tremelimumab remained efficacious regardless of the presence of anti-drug antibodies in unresectable hepatocellular carcinoma.
PTCV Plus pIL-12 and Pembrolizumab Demonstrates Promising Responses in Unresectable/Metastatic HCC
November 8th 2022A regimen consisting of personalized therapeutic cancer vaccine, GNOS-PV02, as well as plasmid-encoded IL-12 and pembrolizumab yielded an overall response rate of 20.9% among evaluable patients with unresectable or metastatic hepatocellular carcinoma.
Sorafenib Plus SBRT Yields Improved Survival Vs Sorafenib Alone in Locally Advanced HCC
October 25th 2022Stereotactic body radiation therapy is a new standard of care option for patients with locally advanced hepatocellular carcinoma, according to a presentation on the phase 3 NRG/RTOG 1112 trial assessing sorafenib combined with stereotactic body radiation therapy.
FDA Grants Orphan Drug Designation to ET140203 T Cells for Hepatoblastoma
October 19th 2022The FDA has given orphan drug designation to ET140203 ARTEMIS, an investigational therapy for hepatoblastoma, the safety and potential efficacy of which are being evaluated in the phase 1/2 ARYA-1 and ARYA-2 studies.